Department of Dermatology and Allergology am Biederstein, Technical University Munich (TUM), Munich, Germany.
Curr Allergy Asthma Rep. 2012 Apr;12(2):85-98. doi: 10.1007/s11882-012-0241-z.
The hypereosinophilic syndromes (HES) are a heterogeneous group of disorders defined as persistent and marked blood eosinophilia of unknown origin with systemic organ involvement. HES is a potentially severe multisystem disease associated with considerable morbidity. Skin involvement and cutaneous findings frequently can be seen in those patients. Skin symptoms consist of angioedema; unusual urticarial lesions; and eczematous, therapy-resistant, pruriginous papules and nodules. They may be the only obvious clinical symptoms. Cutaneous features can give an important hint to the diagnosis of this rare and often severe illness. Based on advances in molecular and genetic diagnostic techniques and on increasing experience with characteristic clinical features and prognostic markers, therapy has changed radically. Current therapies include corticosteroids, hydroxyurea, interferon-α, the tyrosine kinase inhibitor imatinib mesylate, and (in progress) the monoclonal anti-interleukin-5 antibodies. This article provides an overview of current concepts of disease classification, different skin findings, and therapy for HES.
高嗜酸性粒细胞综合征(HES)是一组异质性疾病,其特征为持续性和显著的不明原因的血液嗜酸性粒细胞增多,并伴有全身器官受累。HES 是一种潜在严重的多系统疾病,与相当大的发病率有关。皮肤受累和皮肤表现经常可以在这些患者中看到。皮肤症状包括血管性水肿;不寻常的荨麻疹样病变;和湿疹样、治疗抵抗、瘙痒的丘疹和结节。它们可能是唯一明显的临床症状。皮肤特征可以为这种罕见且常严重的疾病提供重要的诊断线索。基于分子和遗传诊断技术的进步,以及对特征性临床特征和预后标志物的经验不断增加,治疗已经发生了根本性的变化。目前的治疗方法包括皮质类固醇、羟基脲、干扰素-α、酪氨酸激酶抑制剂甲磺酸伊马替尼,以及(正在进行中)单克隆抗白细胞介素-5 抗体。本文概述了 HES 的疾病分类、不同的皮肤表现和治疗的最新概念。